English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

D ipyridamole thallium 201 scintigraphy is increasingly being used as an alternative to exercise scintigraphy for detection of coronary artery disease and risk stratification.1,2 Intravenous infusion of 0.56 mg/kg dipyridamole, the average dose used in clinical studies, causes a significant increase in myocardial blood flow in zones perfused by normal coronary arteries but only a slight increase in zones perfused by stenotic vessels.3 Furthermore, experimental studies have shown that the regional flow alterations distal to a coronary stenosis after intravenous or intracoronary dipyridamole infusion are similar to those produced by intracoronary infusion of adenosine.4 Blood is redistributed from the

Dipyridamole thallium 201 imaging. How safe is it?